Rifampicin vs Rifabutin for Tubercular Pericarditis

Treatment Recommendations

The Centers for Disease Control and Prevention recommends that for HIV-positive patients on protease inhibitors or NNRTIs (except efavirenz with specific regimens), rifabutin should be substituted for rifampicin with appropriate dose adjustments 1, 2
The Centers for Disease Control and Prevention suggests that rifampicin is preferred for HIV-negative patients or those not on antiretroviral therapy, due to its superior efficacy and faster bacteriologic response in approximately 90 controlled clinical trials 3
The Centers for Disease Control and Prevention recommends that for HIV-positive patients on efavirenz-based ART, rifampicin can be used without dose adjustment when combined with efavirenz 600 mg daily plus two NRTIs 1, 4

For HIV-positive patients on dolutegravir-based ART, the Centers for Disease Control and Prevention recommends that dolutegravir must be increased to 50 mg twice daily when used with rifampicin 4
The Centers for Disease Control and Prevention suggests that rifabutin can be used with nevirapine, but with dose adjustments 2

The Centers for Disease Control and Prevention notes that rifabutin may be more reliably absorbed than rifampicin in patients with advanced HIV disease, and appears better tolerated in patients with rifampicin-induced hepatotoxicity 3
The Centers for Disease Control and Prevention recommends that rifabutin has fewer interactions with azole antifungals, anticonvulsants, and methadone 3

The Centers for Disease Control and Prevention suggests that for patients not yet on ART, consider staggered initiation: start TB treatment first, then add ART at the end of the 2-month intensive phase or after TB treatment completion 6
The Centers for Disease Control and Prevention recommends that daily therapy during the intensive phase is preferred, with twice-weekly dosing reserved for the continuation phase 3, 2

The Centers for Disease Control and Prevention recommends that if rifamycins cannot be used due to complex drug interactions or intolerance, a 9-month streptomycin-based regimen can be considered: isoniazid, streptomycin, pyrazinamide, and ethambutol for 2 months, then isoniazid, streptomycin, and pyrazinamide 2-3 times weekly for 7 months 6

The Centers for Disease Control and Prevention recommends that directly observed therapy (DOT) should be used for all HIV-TB co-infected patients 6
The Centers for Disease Control and Prevention suggests that close monitoring for TB treatment failure, antiretroviral treatment failure, paradoxical reactions, and drug toxicities is essential 1, 7